This suggests that measuring KLK proteolysis can be coupled together with routine prostate specific antigen (PSA) testing for improved PCa diagnosis and monitoring, highlighting a role for the use of ABPs to assess KLK activity as a novel PCa biomarker. The gene discussed is KLK3; the disease is posterior cortical atrophy.